Erratum to “The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies”

Abstract

This erratum corrects the following:

Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022;72(1):57–77. doi:10.3322/caac.21704

In the aforementioned article, an error appears in the Head and Neck Radiation Therapy section. The text should read as follows:

“From 59.4% to 100% of patients with H&N cancer who were treated with RT or chemoradiotherapy (CRT) have OM, with SOM affecting approximately 65% of patients.^9,10 The incidence is influenced by tumor site, radiation field, radiation technique, and the use of concomitant chemotherapy. A meta-analysis of 12 prospective trials including 1373 H&N cancer patients reported the incidence of SOM in 2 cisplatin-based CRT protocols. In this meta-analysis, the incidence of SOM was 40% for the high-dose cisplatin protocol (once every 3-4 weeks, 2 cycles) and 75% for the low-dose cisplatin protocol (once a week, 4-7 cycles) (P = .0202).¹¹” It is noteworthy that there was a significant survival benefit (P = .0185) for the high-dose schedule.

The authors apologize for the error.